Figure 2
Figure 2. CD164 binding inhibits CD133+ and Jurkat cell migration. Transwell migration assays using CD133+ cells (A) and Jurkat cells (B). Cells were incubated with the antibodies indicated and stimulated to migrate to CXCL12 presented on fibronectin. The value for untreated migration to CXCL12 was normalized to 100%, and all other migration was compared with this normalized value. Data shown represent the mean ± SEM of 3 to 7 independent experiments. *Antibody treatment caused statistically significant reductions in the number of cells migrating to CXCL12 compared with untreated control (P < .05; 1-paired Student t test). No significant effect occurred on cell migration using a variety of isotype-matched binding and nonbinding mAbs, including that to the sialomucin PSGL-1, in either cell type.

CD164 binding inhibits CD133+ and Jurkat cell migration. Transwell migration assays using CD133+ cells (A) and Jurkat cells (B). Cells were incubated with the antibodies indicated and stimulated to migrate to CXCL12 presented on fibronectin. The value for untreated migration to CXCL12 was normalized to 100%, and all other migration was compared with this normalized value. Data shown represent the mean ± SEM of 3 to 7 independent experiments. *Antibody treatment caused statistically significant reductions in the number of cells migrating to CXCL12 compared with untreated control (P < .05; 1-paired Student t test). No significant effect occurred on cell migration using a variety of isotype-matched binding and nonbinding mAbs, including that to the sialomucin PSGL-1, in either cell type.

Close Modal

or Create an Account

Close Modal
Close Modal